INNATE PHARMA SA (IPH.PA)
FR0010331421 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | 202.89M | |||
| Cash Equivalents | 70.61M | 84.22M | 103.76M | 136.79M | 202.89M | |||
| Marketable Securities | 21.85M | 17.26M | 16.08M | 14.85M | 15.98M | |||
| Receivables | 46.49M | 31.02M | 13.47M | 13.87M | 5.69M | |||
| Other Current Assets | 9.07M | 7.32M | 4.95M | 7.95M | 13.05M | |||
| Total Current Assets | 148.01M | 139.83M | 138.26M | 173.45M | 237.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 6.32M | 8.54M | 10.17M | 11.69M | 11.67M | |||
| Investments And Advances | 9.80M | 35.12M | 39.88M | 38.93M | 37.01M | |||
| Intangibles | 416.00K | 1.56M | 44.19M | 46.29M | 96.97M | |||
| Other Non-Current Assets | 9.01M | 8.57M | 5.03M | 7.09M | 1.28M | |||
| Total Non-Current Assets | 36.18M | 68.03M | 129.24M | 133.97M | 163.76M | |||
| TOTAL ASSETS | 184.19M | 207.86M | 267.50M | 307.42M | 401.36M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 7.09M | 10.22M | 7.00M | 1.83M | 21.30M | |||
| Current Portion Of LT Debt. | 9.49M | 2.10M | 31.17M | 2.15M | 2.13M | |||
| Accrued Expenses | 7.02M | 5.98M | 7.46M | 8.32M | 7.00M | |||
| Accounts Payable | 25.58M | 13.67M | 14.73M | 20.75M | 41.39M | |||
| Other Current Liabilities | 7.47M | 9.36M | 19.53M | 12.44M | 49.99M | |||
| Total Current Liabilities | 39.64M | 41.34M | 79.89M | 45.49M | 121.82M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 75.99M | 93.14M | 46.50M | 61.80M | 16.59M | |||
| Deferred Taxes/Income | 9.01M | 8.57M | 5.03M | 7.09M | 1.29M | |||
| Other Non-Current Liabilities | 7.66M | 10.67M | 28.64M | 37.07M | 44.24M | |||
| Total Non-Current Liabilities | 92.66M | 112.37M | 80.17M | 105.96M | 62.12M | |||
| TOTAL LIABILITIES | 132.29M | 153.71M | 160.06M | 151.45M | 183.94M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -336.40M | -329.50M | -271.76M | -220.10M | -156.14M | |||
| Additional Paid In Capital | 384.25M | 379.64M | 375.22M | 372.13M | 369.62M | |||
| Common Shares | 4.04M | 4.01M | 3.98M | 3.95M | 3.94M | |||
| Other Shareholders' Equity | N/A | N/A | -1.00K | N/A | 1.00K | |||
| Shares Outstanding | 80.84M | 79.52M | 79.52M | 78.97M | 78.79M | |||
| Tangible Book Value per Share | 0.64 | 0.66 | 0.80 | 1.39 | 1.53 | |||
| Total Shareholders' Equity | 51.90M | 54.15M | 107.44M | 155.98M | 217.42M | |||
| TOTAL LIABILITIES AND EQUITY | 184.19M | 207.86M | 267.50M | 307.42M | 401.36M | |||
| Statistics | ||||||||
| Debt/Equity | 1.60 | 1.91 | 0.50 | 0.41 | 0.17 | |||
| Current Ratio | 3.73 | 3.38 | 1.73 | 3.81 | 1.95 | |||
| Return On Assets (ROA) | -4.11% | -27.95% | -19.74% | -20.81% | -5.17% | |||
| Return On Equity (ROE) | -14.59% | -107.30% | -49.15% | -41.02% | -9.55% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | 0.30% | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | 0.71% | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | 1.20% | N/A | |||
All data in EUR